Skip to main content

Table 4 The marginal annual cost - effectiveness and benefit-cost of sif in Ottawa using the first model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada

Variables

Annual cost of operation

Sharing rate

# of HIV averted

# of HCV averted

Cost-effectiveness ratio HCV

Cost-effectiveness ratio HIV

Benefit-cost ratio HCV

Benefit-cost ratio HIV

Cost-benefit ratio Total

Post SIF

$2,182,800

11%

5

48

$45,475

$436,560

0.77

0.48

1.26

  

(14%, 7%)

(6, 3)

(65, 31)

(33,581, $70,413)

($363,800, $727,600)

(1.1, 0.5)

(0.58, 0.3)

(1.63, 0.79)

Two SIF

$2,182,800

8%

4

41

$53,239

$545,700

0.66

0.39

1.05

  

(11%, 5%)

(6, 3)

(55, 26)

($39,687, $83,954)

($363,800, $727,600)

(0.89, 0.42)

(0.58, 0.3)

(1.46, 0.71)

Three SIF

$2,182,800

6%

2

24

$90,950

$1,091,400

0.39

0.19

0.58

  

(9%, 4%)

(3, 1)

(28, 14)

($77,957, $155,914)

($727,600, $2,182,800)

(0.45, 0.23)

(0.29, 0.1)

(0.74, 0.32)

Four SIF

$2,182,800

5%

2

17

$128,400

$1,091,400

0.27

0.19

0.47

  

(7%, 3%)

(3, 1)

(28, 13)

($77,957, $167,908)

($727,600, $2,182,800)

(0.45, 0.21)

(0.29, 0.1)

(0.74, 0.31)

Five SIF

$2,182,800

3%

2

21

$103,943

$1,091,400

0.34

0.19

0.53

  

(5%, 2%)

(3, 1)

(28, 13)

($77,957, $167,908)

($727,600, $2,182,800)

(0.45, 0.21)

(0.29, 0.1)

(0.74, 0.31)

Six SIF

$2,182,800

2%

2

21

$103,943

$1,091,400

0.34

0.19

0.53

  

(3%, 1%)

(3, 1)

(28, 13)

($77,957, $167,908)

($727,600, $2,182,800)

(0.45, 0.21)

(0.29, 0.1)

(0.74, 0.31)

Seven SIF

$2,182,800

1%

2

21

$103,943

$1,091,400

0.34

0.19

0.53

  

(1%, 1%)

(3, 1)

(28, 13)

($77,957, $167,908)

($727,600, $2,182,800)

(0.45, 0.21)

(0.29, 0.1)

(0.74, 0.31)

  1. Note: The numbers in parentheses represent the results of the sensitivity analysis: (30 per cent sharing rate, 10 percent sharing rate).
Back to article page

Substance Abuse Treatment, Prevention, and Policy

ISSN: 1747-597X